PMGC Holdings ELAB
NASDAQ ELAB
$4.70 +0.08 (+1.72%)
As of: Sep 10, 2026 · 12:55 PM EDT

PMGC Holdings (ELAB) Total Current Liabilities (2022 - 2026)

PMGC Holdings' (ELAB) quarterly Total Current Liabilities came in at $15.3 million in Q2 2026, up 4597.67% year-over-year from $326301.0 in Q2 2025, and up 35.68% quarter-over-quarter from $11.3 million in Q1 2026.

Analysis

PMGC Holdings (ELAB) Total Current Liabilities (2022 - 2026) Analysis & Trends

PMGC Holdings has disclosed Total Current Liabilities across 5 years of filings, most recently posting $15.3 million for Q2 2026.

  • In Q2 2026, Total Current Liabilities rose 4597.67% year-over-year to $15.3 million; the TTM figure through Jun 2026 stood at $15.3 million (up 4597.67% YoY), while the FY2025 annual figure was $3.9 million, up 119.12% from the prior year.
  • Total Current Liabilities came in at $15.3 million for Q2 2026 at PMGC Holdings, up from $11.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $1.6 billion in Q3 2023 to a low of $326301.0 in Q2 2025.
  • Average Total Current Liabilities over 5 years is $130.0 million, with a median of $1.9 million recorded in 2024.
  • Year-over-year, Total Current Liabilities tumbled 99.87% in 2024 and jumped 4597.67% in 2026.
  • Over 5 years, Total Current Liabilities stood at $588272.0 in 2022, then soared by 120.54% to $1.3 million in 2023, then surged by 38.68% to $1.8 million in 2024, then surged by 119.12% to $3.9 million in 2025, then soared by 288.82% to $15.3 million in 2026.
  • Per Business Quant data, the three most recent Total Current Liabilities figures were $15.3 million in Q2 2026, $11.3 million in Q1 2026, and $3.9 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Amgen 206.40 Bn 192.42 Bn 7.24 Bn 25.50 Bn
2 Gilead Sciences 180.38 Bn 177.20 Bn 6.22 Bn 11.02 Bn
3 Vertex Pharmaceuticals 131.28 Bn 123.43 Bn 2.84 Bn 3.94 Bn
4 Regeneron Pharmaceuticals 81.73 Bn 73.73 Bn 3.93 Bn 5.53 Bn
5 Argenx Se 60.28 Bn 55.09 Bn 1.37 Bn 1.58 Bn
6 Moderna 54.02 Bn 48.88 Bn 52.00 Mn 2.53 Bn
7 Alnylam Pharmaceuticals 33.28 Bn 29.97 Bn 992.69 Mn 1.51 Bn
8 Biogen 31.81 Bn 30.52 Bn 1.96 Bn 3.92 Bn
9 Roivant Sciences 29.02 Bn 29.02 Bn 1.16 Mn 283.60 Mn
10 PMGC Holdings 2.29 Mn -16.50 Mn 385,691.00 15.33 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 15.33 Mn
Mar 31, 2026 11.30 Mn
Dec 31, 2025 3.94 Mn
Sep 30, 2025 5.46 Mn
Jun 30, 2025 326,301.00
Mar 31, 2025 760,268.00
Dec 31, 2024 1.80 Mn
Sep 30, 2024 2.13 Mn
Jun 30, 2024 1.94 Mn
Mar 31, 2024 1.22 Mn
Dec 31, 2023 1.30 Mn
Sep 30, 2023 1.64 Bn
Dec 31, 2022 588,272.00